- Home
- CGON vs CNMD Comparison
CGON vs CNMD Comparison
Compare CGON & CNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGON
- CNMD
- Stock Information
- Founded
- CGON 2010
- CNMD 1970
- Country
- CGON United States
- CNMD United States
- Employees
- CGON N/A
- CNMD N/A
- Industry
- CGON
- CNMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CGON
- CNMD Health Care
- Exchange
- CGON NYSE
- CNMD Nasdaq
- Market Cap
- CGON 2.1B
- CNMD 1.7B
- IPO Year
- CGON 2024
- CNMD 1987
- Fundamental
- Price
- CGON $26.90
- CNMD $54.33
- Analyst Decision
- CGON Strong Buy
- CNMD Hold
- Analyst Count
- CGON 10
- CNMD 5
- Target Price
- CGON $64.44
- CNMD $62.20
- AVG Volume (30 Days)
- CGON 864.2K
- CNMD 418.9K
- Earning Date
- CGON 08-07-2025
- CNMD 07-30-2025
- Dividend Yield
- CGON N/A
- CNMD 1.47%
- EPS Growth
- CGON N/A
- CNMD 46.38
- EPS
- CGON N/A
- CNMD 3.81
- Revenue
- CGON $662,000.00
- CNMD $1,315,998,000.00
- Revenue This Year
- CGON N/A
- CNMD $6.27
- Revenue Next Year
- CGON $25,206.93
- CNMD $5.62
- P/E Ratio
- CGON N/A
- CNMD $14.26
- Revenue Growth
- CGON 224.51
- CNMD 4.32
- 52 Week Low
- CGON $14.80
- CNMD $46.00
- 52 Week High
- CGON $40.47
- CNMD $78.19
- Technical
- Relative Strength Index (RSI)
- CGON 59.29
- CNMD 49.86
- Support Level
- CGON $25.51
- CNMD $51.43
- Resistance Level
- CGON $27.28
- CNMD $55.19
- Average True Range (ATR)
- CGON 1.01
- CNMD 1.55
- MACD
- CGON 0.02
- CNMD 0.18
- Stochastic Oscillator
- CGON 89.23
- CNMD 76.74
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
About CNMD CONMED Corporation
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.